Mammalian cytoskeletons are complex networks of protein filament structures that extend throughout the cytoplasm. Cytoskeletons are classified into just three groups: actin filaments, intermediate filaments, and microtubules. Each type of filament is formed from a different protein monomer and can be built into a variety of structures according to its associated proteins. Actin filaments and microtubules are dynamic structures whose lengths are controlled by polymerization and depolymerization. Actin and microtubules utilize the energy of nucleotide hydrolysis for polymerization, and the extent of their polymerization is dynamically regulated by their associated proteins, whose activities are also regulated by intracellular or extracellular environment. Polymerization dynamics are central to their biological functions, and allow both actin filaments and microtubules to adopt spatial arrangements that can change rapidly in response to cellular needs. 1, 2) Therefore, one type of actin or microtubule inhibitors interferes with the polymerization states. For example, cytochalasins and latrunculins inhibit actin filament formation by disclosing the polymerization-competent actin monomer (G-actin), [3] [4] [5] [6] and phalloidin and jasplakinolide inhibit depolymerization of actin filament (Factin) by strengthening the actin-actin interaction. [7] [8] [9] [10] On the other hand, actin filaments and microtubules function not only as mechanical networks, but also as ''railroads'' for motor proteins. Motor proteins transport several cargos, such as transport vesicles, unfolded/ misfolded proteins, and chromosomes, that are important materials for cell-to-cell communication, cell survival, and cell cycle progression respectively. 11) Furthermore, motor proteins transport actin filaments and microtubules, and generate the motive force for cell motility and organelle movement. Therefore, the inhibitors against motor proteins are a novel type of cytoskeleton inhibitors.
Since cytoskeletons themselves and associated proteins play in several important cellular processes, both types of inhibitor are expected to be useful not only as antitumor agents, but also as tools for understanding a wide variety of the cellular functions of cytoskeletons. Indeed, a large number of compounds have been reported to be anti-microtubule or anti-actin agents, and some compounds, such as vinca alkaloids and taxoids, are used clinically as anti-tumor drugs. 12) To understand the inhibition mechanisms and development of specific/clinically available inhibitors, it is important to determine the binding sites of these drugs to their target proteins. Latrunculin A clamps the ATP binding site, suggesting that this compound inhibits actin polymerization by inhibiting nucleotide exchange.
gesting that both compounds mimic the binding of gelsolin-family proteins. 14, 15) Actin filament stabilizers phalloidin, jasplakinolide, and dolastatin 11 bind in the gap between the two long-pitch F-actin strands, and it has been speculated that the connection between the strands might be the key to F-actin stabilization. 16) These studies clearly show that investigation of the drug binding sites is informative for elucidating the inhibitory mechanisms.
Small molecules originating from natural organisms are an important chemical source for drug development. [17] [18] [19] Although recent great progress in combinatorial chemistry and diversity-oriented synthesis has made it possible to serve a large number of synthetic compounds for investigation of drug seeds, the chemical space (diversity of compounds) of synthetic compounds is still narrow compared with that of natural products. Therefore, we have focused on and investigated natural products that interfere with the cellular functions. In this review, I summarize our recent research into the molecular targets and/or the inhibition mechanisms of anti-actin and anti-microtubule natural products.
I. Small Molecules Interfere with the Functions of Actin Cytoskeleton
Anticancer drug development strategies have traditionally focused on direct inhibition of cancer cell growth. However, other rate-limiting processes in the progression of cancers are also promising targets for intervention. Tumor cell invasion and metastasis, later points in cancer progression, are thought to be inherently involved in cell motility. 20) Therapeutic agents that potently inhibit invasion and metastasis might be effective in restraining new tumor formation. Since invasion, cell migration, and cell division are dependent on the actin cytoskeleton, actin and its associated proteins are attractive targets for the development of new chemotherapies. 21, 22) 1. Phoslactomycins (PLMs) Phoslactomycins (PLMs) are compounds containing ,-unsaturated -lactone. They are originally isolated as antifungal antibiotics from the soil bacteria species Streptomyces (Fig. 1) . 23, 24) Several related compounds, phosphazomycins, 25, 26) phospholine, 27, 28) and leustroducsins, 29, 30) have been reported as antifungal antibiotics, or as inducers of a colony-stimulating factor in bone marrow stromal cells. These compounds commonly contain not only an ,-unsaturated -lactone, but also an amino group, a phosphate ester, and a cyclohexane ring, but have different substituents bound to the cyclohexane ring (Fig. 1) . However PLMs were isolated as antifungal compounds, we noticed that they induce actin filament depolymerization in murine fibroblast NIH/3T3 cells. 31) This effect was reversible, and actin filaments were reformed 1 h after removal of the inhibitors. Since PLM-F had no effect at all on polymerization of purified actin in vitro, it is thought that PLMs induce actin depolymerization through an indirect mechanism. An in situ phosphorylation assay revealed that PLM-F treatment stimulated the phosphorylation of intracellular vimentin by the inhibition of phosphatase. An in vitro assay showed that PLMs specifically inhibited protein phosphatase type-2A (PP2A) at lower concentrations than protein phosphatase type-1 (PP1). These results suggest that PLMs are PP2A-specific inhibitors and that PP2A is involved in regulation of the organization of the actin cytoskeleton.
Recently, the inhibitory mechanism of PLMs was clarified by Teruya et al. 32) They synthesized biotinylated PLM-A and investigated the binding proteins in mouse liver extract. They found three proteins to which biotinylated PLM-A covalently binds. These proteins were identified as PP2A family proteins: PP2Ac (catalytic subunit of PP2A), PP4, and PP6. Furthermore, they identified the binding site on PP2Ac as Cys269, which is located at the entrance to the catalytic site. This cysteine residue is conserved in PP2A family proteins but not even in PP1, the most closely similar phosphatase. These results strongly suggest that Cys269 is a PP2A-specific gatekeeper residue, and that compounds targeting this residue are PP2A-specific inhibitors.
Amphidinolide H (AmpH)
Amphidinolides are a series of unique cytotoxic macrolides isolated from dinoflagellates Amphidinium sp., that were separated from marine acoel flatworms Amphiscolops sp. 33) Amphidinolide H (AmpH) is a potent cytotoxic 26-membered macrolide possessing unique structural features such as an allyl epoxide and vicinally located one-carbon branches (Fig. 1) . 34, 35) From the structure-activity relationship of AmpH-type macrolides, it was found that the presence of an allyl epoxide, an S-cis-diene moiety, and the ketone at C-20 are important for cytotoxicity. 36) Although AmpH shows potent cytotoxicity to several carcinoma cell lines at the picogram level, the target molecule was unclear. We were interested in the molecular target of AmpH and commenced analysis of phenotypes of AmpH-treated cells. Immediately after starting this analysis, we found that AmpH drastically and irreversibly deformed the actin fibers ( Fig. 2A) .
37) The actin stress fibers had completely disappeared, and only a few disorganized aggregates remained in the cells. In vitro polymerization/depolymerization assay using purified actin indicated that AmpH stimulated actin polymerization and stabilized F-actin.
If the compound covalently binds to its target molecule, it is relatively easy to determine the binding site. [38] [39] [40] [41] Fortunately, AmpH possesses an allyl epoxide ( Fig. 1) , a reactive moiety that can bind hydroxyl, amino, and sulfhydryl moieties. 36) Hence there was a possibility that AmpH covalently binds actin. As expected, the covalent binding of AmpH to actin was elucidated by MALDI-TOF mass spectrometory (Fig. 2B) , and its binding site was determined to be Tyr200 in the actin subdomain 4 using yeast cells harboring site-directed mutagenized actin. This site is close to the actin-actin contact between subdomain 4 of one subunit and subdomain 1 of the diagonally located subunit in the F-actin model as refined by Tirion and coworkers (Fig. 2C) . 42) Therefore, strengthening the diagonal contact, either directly by binding of the drug or through the conformational change induced by drug binding, should induce F-actin stabilization.
II. Small Molecules Interfere with the Functions of Microtubules
Mitosis is the process by which eukaryotic cells ensure equal distribution of their chromosomes at cell division. Progression through mitosis is inhibited by the spindle checkpoint until the chromosomes are properly aligned on the mitotic spindle. 43) Since most cells in the human body do not actively divide in comparison to cancer cells, a drug that activates the spindle checkpoint might be useful in the treatment of malignant tumors that show rapid and abnormal cell proliferation. Microtubule inhibitors activate spindle checkpoint control through the inhibition of microtubule dynamics, and some of the most useful cancer therapeutic agents are categorized in microtubule inhibitors.
44)

Tryprostatin A (TPS-A)
Tryprostatin A (TPS-A) was isolated from Aspergillus fumigatus BM939 as cell cycle inhibitors that arrest mammalian cell proliferation in the M phase (Fig. 1) . [45] [46] [47] Since TPS-A induced reversible disruption of the cytoplasmic microtubules in a range of concentrations that specifically inhibited M phase progression, it was thought that TPS-A is a microtubule inhibitor. 48) It is known that most microtubule inhibitors targettubulin and inhibit microtubule assembly or disassembly in situ and in vitro. [49] [50] [51] Like other microtubule inhibitors, TPS-A inhibited in vitro microtubule assembly in a dose-dependent manner. This result clearly indicated that TPS-A is a microtubule assembly inhibitor. Because microtubule consists of tubulin, a major constituent and the main body of a microtubule, and MAPs (microtubule-associated proteins), which function as intrinsic polymerization inducers, the direct effect of TPS-A on tubulin assembly was investigated. To start polymerization of purified tubulin, it is necessary to add a polymerization inducer instead of MAPs. [52] [53] [54] In direct straight contrast, TPS-A did not inhibit the in vitro tubulin assembly stimulated by glutamate, a nonphysiological assembly inducer. Since most microtubule inhibitors inhibit both microtubules and tubulin assembly, these results suggest that TPS-A inhibits microtubule assembly by a novel mechanism. The difference between microtubules and tubulin assay is the assembly inducer. After testing several assembly inducers, it was found that TPS-A specifically inhibits the tubulin polymerization stimulated by assembly inducer effects on the C-terminal domain of tubulin (MAP2, tau, and poly-L-lysine), but not that by other inducer (glutamate and taxol). Apart from these inducers, tubulin S, a tubulin heterodimer from which the C-terminal domain has been removed enzymically, underwent assembly in the absence of MAPs and inducers. 55) Although colchicine inhibited tubulin assembly irrespective of the species of inducer, TPS-A did not inhibit tubulin S assembly. These results strongly suggest that TPS-A inhibits C-terminal domain-mediated microtubule assembly (Fig. 3A) .
TPS-A is the first natural compound that inhibits microtubule assembly by interfering with the interaction between MAPs and the C-terminal domain of tubulin. Many organic chemists aim at synthesizing cancer chemotherapeutic reagents modeled on TPS-A and TPS-B. [56] [57] [58] [59] [60] With tryprostatins as a basis, it might be possible to develop new agents, useful both as experimental inhibitors in the study of microtubules and in cancer therapy.
Pironetin
Pironetin (Fig. 1 ) was isolated as a plant-growth regulator that induces shortening of the plant height of rice, 61, 62) and as an immunosuppressor that inhibits the blastogenesis of both T and B cells. 63) In the course of investigating the molecular mechanisms, we found that pironetin showed antitumor activity against a murine tumor cell line, P388 leukaemia, transplanted in mice, and induced apoptosis via disruption of the cellular microtubule network in situ. 64) Apart from TPS-A, pironetin inhibited microtubule-associated protein-induced, and glutamate-induced tubulin assembly in vitro, clearly showing that pironetin is a tubulin inhibitor that inhibits tubulin polymerization by binding to tubulin directly.
Pironetin has a unique structure containing only one pyran residue and an alkyl chain. This is simpler than the structures of other M phase inhibitors (Fig. 1) . To create a new drug useful in cancer therapy from pironetin as a lead compound, it is important to determine the binding site on tubulin. The primary target molecule of most tubulin inhibitors is -tubulin, and such compounds can be placed in one of three categories on the basis of the binding kinetics totubulin: (i) colchicine, colcemid and podophyllotoxin, which bind to the colchicine-binding site; 51, [65] [66] [67] (ii) vinblastine and vincristine, which bind to the vinblastine-binding site; [68] [69] [70] and (iii) rhizoxin and maytansine, which bind to the maytansine-rhizoxin-binding site (Fig. 3A) . 71, 72) Binding competition experiments with turally unidentified, we continued to attempt to identify the pironetin-binding site. 73) According to structureactivity relationship analyses, it was speculated that pironetin covalently binds tubulin by Michael addition via its ,-unsaturated -lactone.
74) Biotinylated pironetin, which inhibited tubulin assembly both in vitro and in situ, covalently bound with tubulin, and its binding was inhibited by natural pironetin. 75) The finding that inactive pironetin derivatives failed to bind tubulin in situ suggests that covalent binding is important to inhibit tubulin polymerization.
Although it is known that compounds that bind to their target proteins by Michael addition bind to the sulfhydryl group of cysteine residues or the "-amino group of lysine residues, most compounds bind to the sulfhydryl group of cysteine residues. 32, [76] [77] [78] [79] [80] However, it is assumed that pironetin binds to the "-amino group of lysine, because tubulin binding by pironetin is labile under acidic and basic pH conditions. These results suggest that retro-Michael addition readily occurs under nonphysiological pH conditions. Partial proteolytic analyses of biotinylated pironetin-bound peptides, followed by systematic alanine scanning of cysteine and lysine residues, strongly suggested that Lys352 oftubulin is the pironetin binding site. This is surprising, because the reactivity of the "-amino group of lysine is quite low compared with that of the sulfhydryl group of cysteine. In silico analysis of the pironetin-tubulin complex suggested that helixes 8/10 and sheet 8 form a cavity that fits pironetin well, and that pironetin binding with Lys352 and Asn258 disrupts the hydrogen network among Glu254, Lys352, and Asn258 (Fig. 3B) . Because it is speculated that Asn258 forms a hydrogen bond network with Glu254 via Lys352, and Glu254, a residue conserved in essentially all -tubulins, is in an ideal position to be involved in the hydrolysis of GTP of the E site in -tubulin, pironetin binding might influence the GTP hydrolysis activity of Glu254.
Pironetin binds -tubulin, but how does pironetin inhibit vinblastine binding on -tubulin? Recent progress on tubulin structure clearly answers this question. Gigant et al. clarified the structure of vinblastine bound to the tubulin-colchicine:RB3-SLD complex, and showed that vinblastine binds not only to -tubulin but also on a hydrophobic groove on the -tubulin surface that is located at an intermolecular contact in microtubules. 68) They further found that a pironetin-binding residue, Lys352, is part of the vinblastine binding site, suggesting that the binding sites of pironetin and vinblastine overlap, and that these drugs occupy the same site competitvely. Combining their previous reports that Lys350 of -tubulin, at analogous positions on different subunits, is involved in colchicines binding, and that the colchicine B ring interacts with -tubulin in addition to A/C ring interaction with -tubulin, 65) there is a possibility that the colchicine and pironetin/vinca alkaloid binding sites are similar sites, but at different subunit interfaces. 81) How does pironetin inhibit microtubule polymerization? The effects of pironetin on vinblastine and colchicine binding to tubulin are similar to that of vinblastine, that is, both pironetin and vinblastine stimulate colchicine binding to tubulin. These results and recent structural evidence strongly suggest that pironetin induces conformational changes of interdimer interaction, as observed in the case of vinblastine.
In conclusion, pironetin is a unique compound that binds to -tubulin with highly site-selective binding to the "-amino moiety of lysine by Michael addition. These data have important implications for the design of molecularly targeted small molecules.
Terpendole E (TerE)
As mentioned previously, compounds that activate spindle checkpoint are useful cancer therapeutic agents. 82, 83) However, these drugs directly target tubulins and inhibit several dynamic processes dependent upon microtubule activity, such as maintenance of organelles, cell shape, cell motility, and transport of vesicle and organelles. 2, 84, 85) Moreover, microtubule inhibitors sometimes cause severe side effects in nonproliferating neuronal cells. 86) In order to avoid such side effects, specific inhibitors that affect the function of the target molecule required for M phase progression would be useful.
During the screening of microbial products to find specific M phase inhibitors that do not directly target tubulins, terpendole E (TerE; Fig. 1 ) was rediscovered. 87, 88) TerE did not affect microtubule integrity in the interphase, but induced a monoastral microtubule array that was surrounded by a ring of chromosomes with unseparated centrosomes (Fig. 4) . This phenotype resembles that of a mutant of mitotic kinesin Eg5, a member of the BimC family, [89] [90] [91] and in vitro motility assay indicated that TerE inhibited motor activities of human Eg5 (the IC 50 value was 14.6 mM), but did not affect conventional kinesin from either Drosophila or the bovine brain. Although terpendoles have been reported to be inhibitors of acyl-CoA:cholesterol Oacyltransferase (ACAT), the Eg5 inhibitory activity of TerE was independent of ACAT inhibition. Taken together, these results indicate that TerE is a novel Eg5 inhibitor isolated from a fungal strain.
Recently, mitotic kinesin, including Eg5, has been recognized as an attractive target for antitumor compounds. After finding the first Eg5 inhibitor, monastrol, 92) several research groups and pharmaceutical companies have tried to identify Eg5 inhibitors with novel structures, and some of them are now in phase trial. [93] [94] [95] [96] [97] [98] However, only TerE is a natural compound, and it should be useful to screen natural compounds to obtain Eg5 inhibitors with unique structures.
III. Concluding Remarks
Cytoskeletons are self-assembled filament structures that function in several cellular processes. Since microtubules and actin filaments have important roles in cell cycle progression and migration, they are attractive targets for anticancer drugs. In this review, the inhibition mechanisms and binding sites of anti-actin/microtubule natural products are discussed. Phoslactomycins and pironetin contain =-unsaturated -lactone and covalently bind to cysteine on PP2A and lysine on -tubulin, respectively. AmpH also contains a reactive moiety, allyl expoxide, and covalently binds to actin. The feature that covalently bound their target molecules was helpful to determine their binding sites at the amino acid residue level.
Investigation of binding site clarified that AmpHbinding site is close to the actin-actin contact region in the F-actin model, and that pironetin-binding site ontubulin is near to the interface between tubulin heterodimers. These results suggest that both drugs bind on the protein-protein interface, and perturb actin and microtubule dynamics. Recent structural studies strengthen this speculation; (i) the tubulin inhibitors colchicine and vinblastine bind to the interfacial region of the intradimer and interdimer regions on microtubule, respectively; (ii) actin inhibitors phalloidin, jasplakinolide, and dolastatin 11 bind to the actin-actin contact site. These results strongly suggest that the compound targeting the cavity created by protein-protein interaction might be a drug that interferes with protein dynamics or turnover. In this context, TPSs might be drugs that interfere with the interaction between the C-terminal region of tubulin and MAPs. The binding constant of TPS-A to tubulin is quite high (unpublished results), suggesting that TPS-A cannot bind to tubulin directly. The inhibition rate of TPS-A was not dependent on the concentration of the assembly inducer, poly-L-lysine. One of the derivatives, cyclotryprostatin D stimulated microtubule polymerization. 99) These results suggest that TPS-A binds on the cavity created by tubulin-MAPs interaction. Furthermore, there is a possibility that TerE also interferes with the interaction between the C-terminal domain of tubulin and Eg5. It is interesting that TerE and TPSs contain the structure feature in common, indole ring ( Fig. 1) , suggesting that the indole ring possesses the activity of tubulin interaction. It might be possible to create MAP-specific inhibitors by changing the other parts of compounds. 
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